Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Subcutaneous immunotherapy in adult and pediatric subjects with peanut allergy

An Allergy Case Study

Read the Case Study

About the Case Study

Pharm-Olam was contracted to assess subcutaneous immunotherapy in adult and pediatric subjects with peanut allergy. The safety of the substance had already been confirmed in a First-In-Human (FIH) preliminary study. The research was critical in that there is no effective treatment for peanut allergies and there is a significant need.

The Phase I study population involved incremental dosing of three age groups across seven sites. Each cohort was randomized, double-blind, and placebo-controlled. Dosing was complex, but we overcame the challenge through agile study management.

Program Overview: Phase I

Indication: Evaluation of the safety and tolerability of a SCIT-treatment in adults, adolescents, and pediatric patients with peanut allergy.

 



 

How can we help you create a healthier world?

Talk to one of our experts today.

Please choose one.

Contact Us